ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
Dow Jones
37.903,29
0,23%
Euro vs US Dollar
1,07202
0,02%
Bitcoin
57.408,09
-1,42%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) News

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IONS
DatumZeitQuelleÜberschriftSymbolFirma
25/04/202413h00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
23/04/202413h05PR Newswire (US)Ionis to hold first quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
07/04/202415h48PR Newswire (US)Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
01/04/202413h05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
28/03/202412h05PR Newswire (US)Ionis to hold olezarsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
25/03/202413h18PR Newswire (US)Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingNASDAQ:IONSIonis Pharmaceuticals Inc
13/03/202412h00PR Newswire (US)Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHNASDAQ:IONSIonis Pharmaceuticals Inc
06/03/202413h30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202401h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202401h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202401h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202401h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202401h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202415h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202415h05PR Newswire (US)Ionis announces new chief global product strategy officer to lead next phase of commercial growthNASDAQ:IONSIonis Pharmaceuticals Inc
28/02/202413h05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
21/02/202417h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
21/02/202413h00PR Newswire (US)Ionis reports fourth quarter and full year 2023 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
20/02/202416h39Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
17/02/202401h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
16/02/202422h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
15/02/202413h00PR Newswire (US)Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
14/02/202416h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IONSIonis Pharmaceuticals Inc
13/02/202412h09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
08/02/202413h00PR Newswire (US)Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathyNASDAQ:IONSIonis Pharmaceuticals Inc
07/02/202413h05PR Newswire (US)Ionis to hold fourth quarter and full year 2023 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202401h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202401h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202401h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202401h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS

Kürzlich von Ihnen besucht

AMEX
SPY
SPDR S&P 500
CCOM
US500
US 500
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
CCOM
US30
US 30
TG
MBG
MercedesBenz
CCOM
US100
US Tech 100
TG
BAYN
Bayer
TG
TUI1
Tui
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
AMEX
XLF
Financial Select Sector
NYSE
JPM
JP Morgan Chase
TG
DBK
Deutsche Bank
DBI
SDXP
SDAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten